The discovery that antigen-encoding DNA plasmids could stimulate humoral and cellular immune responses represents a pivotal milestone in vaccine research ( 1 -3 ) . This discovery enabled the development of one of the most promising vaccination strategies against HIV, the so called " prime-boost " strategy in which the immune response is primed with a plasmid DNA (pDNA) and subsequently boosted with a viral vector such as modifi ed vaccinia virus Ankara (MVA) or adenovirus expressing the relevant antigens ( 4 -7 ) . Studies in nonhuman primates (NHPs) suggest that such prime-boost strategies typically induce antigen-specifi c CTL responses and result in a lowering of the viral load upon challenge, although they do not clear the infection ( 8 -10 ) . In humans, although DNA vaccines have been shown to induce immune responses against several pathogens (such as malaria, hepatitis B, and HIV), a major limitation is their poor protective immunogenicity despite the high doses of DNA used ( 7, (11) (12) (13) . Therefore, strategies to optimize the immunogenicity of DNA vaccines are clearly needed.
Recent advances in our understanding of the immune system suggest that the innate immune system, particularly DCs and pattern recognition receptors such as Toll-like receptors (TLRs), plays a critical role in initiating adaptive immune responses and in modulating their strength and quality. Thus, there is presently much interest in understanding the nature of the innate immune parameters that qualitatively govern diff erent types of adaptive immune responses, as well as in exploiting these in the development of novel vaccines against global pandemics and chronic infections such as HIV ( 14 ) . In this context, given the critical roles played by DCs and TLRs in adaptive immunity, they represent promising targets for boosting vaccine immunogenicity ( 15, 16 ) . Numerous previous studies have demonstrated the effi cacy of using TLR ligands (TLR-Ls) in augmenting both cellular and humoral immune responses to protein antigens or DNA-encoded antigens in mice ( 17 -20 ) . Furthermore, recent studies using NHPs have demonstrated that a TLR7/ 8-L formulated or covalently linked to recombinant Gag results in an enhancement in the magnitude and " quality " of the T cell response ( 21, 22 ) . Importantly, TLR-Ls are beginning to be used as vaccine adjuvants in humans. For example, monophosphoryl lipid A, an agonist of TLR4, is being developed by GlaxoSmithKline for use as a vaccine adjuvant and was recently licensed in Europe as a component of an improved vaccine for hepatitis B (Fendrix) ( 23 ) . The TLR9-L CpG DNA has been administered with the hepatitis B vaccine Engerix-B and was shown to enhance the frequency of seroconversion as well as the magnitude of the antibody response ( 24, 25 ) . However, in the case of DNA vaccines, despite several experiments demonstrating the induction of strong immunity in mice ( 1 ), translation into NHPs or humans has been disappointing.
We performed a preclinical vaccine study in rhesus macaques to test the hypothesis that activated DCs would elicit robust levels of antiviral immunity in prime-boost vaccination against HIV. To this end, we have harnessed the ability of Fms-like tyrosine kinase 3 (Flt3) -ligand (FL) to enhance DC numbers in vivo ( 26 -31 ) and specifi c ligands for TLR9 (CpG DNA type B) ( 19, 32 ) and TLR7/8 (3M compound 003) to induce DC activation in a rhesus model. Our data suggest that adjuvanting a DNA vaccine with a single injection of CpG DNA at the time of priming results in a pronounced enhancement of the magnitude of the antigen-specifi c CD8 ϩ T cell response and translates into improved control of viral loads after challenge with SIV. 
TLR9-L and TLR7/8-L induce activation of FL-expanded DCs and monocytes in vivo
We next evaluated whether injection of TLR9-L or TLR7/ 8-L resulted in the activation of APCs in vivo. Animals were injected i.d. with TLR9-L or TLR7/8-L mixed with pDNA on day 15 ( Table I ) and 1 d later (on day 16; Fig. 1 C , red line), and the activation of DCs was evaluated by the up-regulation at day 14; Fig. 1 B ) . A 4.8-fold increase in the frequency of monocytes (HLA-DR ϩ CD14 ϩ ) was also noted (from 3.9 Ϯ 2.63% at day 0 to 10.74 Ϯ 7.43% at day 14). In contrast, FL increased the numbers of pDC precursors only 2.5-fold (from 0.041 Ϯ 0.025% to 0.094 Ϯ 0.075%). These observations are consistent with previous studies ( 30, 31, 33 ) and demonstrate that FL is a very potent DC growth factor in vivo. Gating strategy for APC populations in FL-treated animals. Total PBMCs were isolated using standard procedures, and the mononuclear fractions were analyzed by fl ow cytometry to assess the frequencies of various APCs in the blood. Total DC population subsets were defi ned by a lack of lineage marker expression (CD3 Ϫ CD14 Ϫ CD20 Ϫ ) and expression of HLA-DR. CD11c ϩ DCs were defi ned as CD11c ϩ HLADR ϩ Lin Ϫ , and pDCs were defi ned as CD123 ϩϩ HLA-DR ϩ CD11c Ϫ Lin Ϫ . Monocytes were defi ned as HLA-DR ϩ CD14 ϩ within the entire PBMC population. (B) Animals were injected subcutaneously with 100 g/kg FL daily from days 0 to 14. The frequencies of specifi c APC subsets in the blood at the indicated time points are shown. Numbers in squares represent the mean fold increase between days 0 and 14. Error bars represent SD. Mean frequencies of specifi c APC subsets at days 0 and 14 were compared by a nonparametric Mann-Whitney test ( n ϭ 5). P Ͻ 0.05 was considered statistically signifi cant (* signifi cantly enhanced ( Fig. 2 A ) . Interestingly, FL ϩ TLR7/ 8-L did not enhance the magnitude of the response despite potent activation of DCs and monocytes ( Fig. 2 A ) . Consistent with these results, there was also a signifi cant enhancement of the Gag and Env-specifi c IFN-␥ -secreting cells, as measured by ELISPOT, in the animals that received FL ϩ TLR9-L relative to group 1 (for the Gag-specifi c response, a mean of 1,500 spots per 10 6 PBMCs, with one animal showing 3,700 spots per 10 6 PBMCs; Fig. 2 B ) . Furthermore, even after the fi rst MVA boost, there was a nearly eightfold enhancement in the frequency of IFN-␥ ϩ CD8 ϩ T cells per total CD8 ϩ T cells in the group that received FL + TLR9-L (0.8%) relative to group 1 (0.1%; Fig. 2 C ) , and there was a large augmentation in the Env-specifi c CD8 ϩ T cell response in group 3 (FL ϩ TLR9-L) relative to group 1 or 2 ( Fig. 2 C ) . The FL ϩ TLR7/8-L group showed no major increase in the magnitude of the response ( Fig. 2 C ) . In addition to the magnitude, the quality of a T cell response is thought to correlate with protection ( 36, 37 ) . One measure of T cell quality is based on the frequency of polyfunctional antigen-specifi c T cells that simultaneously produce IFN-␥ , TNF-␣ , and IL-2 ( 38, 39 ) . We thus evaluated the frequencies of such cells by ICC staining at weeks 1 or 10 after the second MVA boost. There was a very marked increase in the frequency of polyfunctional CD8 ϩ T cells that simultaneously produced IFN-␥ , TNF-␣ , and IL-2 in the FL ϩ TLR9-L group relative to group 1 ( Fig. 2 D ) . At the peak of the response (1 wk after second MVA), the frequencies of polyfunctional CD8 ϩ T cells in the FL ϩ TLR9-L group (group 3) were higher than in groups 1 and 2, and this was also apparent 9 wk later ( Fig. 2 D ) . However, relative to the total antigen-specifi c T cell responses, even the unadjuvanted control group 1 monkeys exhibited a strikingly high representation of polyfunctional cells (up to 36% of the antigen-specifi c cytokine-producing T cells; Fig. S3 , available at http://www.jem.org/cgi/content/full/jem.20071211/DC1). Furthermore, the majority of IFN-␥ -producing cells produced at least one other cytokine (Fig. S3) . However, no enhancement of the relative representation of polyfunctional CD4 ϩ or CD8 ϩ T cells was noted in group 2, 3, or 4 compared with group 1 (Fig. S3 ).
An important caveat to this experiment was the unequal distribution of Mamu-A*01 animals in each group. Animals in groups 2, 3, 4, and 5 contained, respectively, 3, 4, 3, and 2 animals typed positive for the Mamu-A*01 allele with PCR analyses. Group 1 did not contain Mamu-A*01 -positive animals. Animals that express Mamu-A*01 have been shown to be particularly effi cient at controlling SIV replication ( 40, 41 ) . However, recent experiments ( 42 ) and our own results (unpublished data) suggest that this may not be the case. Nevertheless, it was important to determine the extent to which the diff erences in the immune responses could be attributable to Mamu-A*01. Therefore, we initially analyzed the magnitude of the Gag-specifi c IFN-␥ ϩ CD8 ϩ T cell response only in Mamu-A*01 ϩ animals. As indicated in Fig. 2 E , the Gagspecifi c IFN-␥ ϩ CD8 ϩ T cell responses were enhanced in of the co-stimulatory molecules CD80 and CD86 relative to the peak of APC expansion at day 14 ( Fig. 1 C , black line) . The expression of CD80 was substantially up-regulated on both CD11c ϩ DCs and monocytes in animals that received the pDNA plus TLR7/8-L or TLR9-L (red line) in comparison with the group that received the pDNA alone ( Fig. 1,  C and D ) . CD86 expression on CD11c ϩ DCs was considerably enhanced by TLR7/8-L, but not by TLR9-L, and was not up-regulated on monocytes by either ( Fig. 1, C and D ) . The reasons for the diff erential induction of co-stimulatory molecules on the distinct APC subsets by TLR9-L versus TLR7/8 are at present unclear. Furthermore, because TLR9 is reported not to be expressed by CD11c ϩ DCs or monocytes ( 35 ) , their observed activation in vivo is likely to have been caused indirectly by proinfl ammatory cytokines rather than by direct TLR9-L -mediated stimulation of these cells. In this context, pDCs that express TLR9 and TLR7 ( 35 ) were diminished in numbers 1 d after the injection of TLR9-L or TLR7/8-L (unpublished data), likely refl ecting the rapid migration of these cells into secondary lymphoid organs in response to stimulation with the TLR-Ls. Furthermore, induction of CD80 and CD86 on the remaining blood pDCs was not enhanced by injection of TLR9-L or TLR7/8-L.
A single injection of TLR9-L into FL-treated animals at the time of initial DNA priming markedly enhances the magnitude of polyfunctional, antigen-specifi c CD8 ؉ T cells after the MVA boost Antigen-specifi c CD8 ϩ and CD4 ϩ T cell responses were evaluated using intracellular cytokine (ICC) staining and ELISPOT 2 wk after each immunization with the DNA vaccine (i.e., weeks 4 and 13) or 1 wk after each boost with MVA (i.e., weeks 37 and 59; Fig. S1 ). For SIV Gag stimulation, one pool of overlapping peptides spanning the entire Gag protein was used to assess the frequencies of Gag-specifi c CD8 ϩ T cells. To measure Env-specifi c T cell responses, the pool of peptides encompassing the full-length HIV Env protein was used in both ICC and ELISPOT assays. After the fi rst or second DNA vaccination, the magnitudes of the antigen-specifi c CD8 ϩ or CD4 ϩ T cell responses were below the threshold of detection in all groups ( Fig. 2 C ; and not depicted).
The monkeys were boosted with 10 8 PFU rMVA 25 wk after the second DNA vaccination (week 36) and a second time on week 58 ( Table I ) . Immune responses were measured 1 wk after each MVA boost by ICC and ELISPOT. CD3 ϩ CD8 ϩ and CD3 ϩ CD4 ϩ T cells were analyzed for IFN-␥ , TNF-␣ , and IL-2 intracellular staining, as shown in Fig. S2 (available at http://www.jem.org/cgi/content/full/ jem.20071211/DC1). Robust responses could be detected, particularly after the second MVA boost ( Fig. 2 ) . The magnitude of the Gag-specifi c CD8 ϩ T cell response in the TLR9-L -injected group was considerably enhanced after the second MVA boost (with a mean frequency of 1.5% Gag-specifi c CD8 ϩ IFN-␥ ϩ T cells) relative to group 1 ( Fig. 2 A ) . The frequency of Env-specifi c CD8 ϩ IFN-␥ ϩ T cells was also Table I and Fig. S1 , and PBMCs were stimulated as described. Each line represents the mean of all individuals in the group Ϯ SD ( n ϭ 5). (D) Frequencies of multicytokine IFN-␥ -, TNF-␣ -, and IL-2 -producing Gag-specifi c T cells after the second rMVA boost vaccination. Total PMBCs at weeks 1 (left) and 10 (right) after the second rMVA boost vaccination were stimulated with a pool of overlapping Gag peptides and stained for intracellular IFN-␥ , TNF-␣ , and IL-2. Percentages of cells simultaneously producing all three cytokines of total Gag-specifi c CD8 ϩ T cells are shown. Error bars represent the mean frequencies Ϯ SEM. All vaccinated groups were compared with group 1 by a nonparametric Mann-Whitney test. P Ͻ 0.05 was considered statistically signifi cant ( n ϭ 5). (E) Frequencies of IFN-␥ -producing Gag-specifi c CD8 ϩ T cells at week 1 after a second rMVA boost vaccination in Mamu-A*01 -positive animals from groups 2, 3, and 4. Each symbol represents an individual animal in the experimental group. Error bars represent the mean frequencies Ϯ SEM ( n ϭ 3 or 4). N.A., not available. group 3, relative to group 2 or 4, suggesting that the enhanced immune response induced by FL + TLR9-L was not simply caused by the unequal distribution of Mamu-A*01 animals. Also, specifi c CD8 ϩ T cell responses against HIV Env protein, which does not demonstrate Mamu-A*01 -specifi c epitope dependence, were enhanced only in group 3, treated with FL and TLR9-L ( Fig. 2 C ) . Collectively, these data suggest that a single injection of TLR9-L at the time of DNA priming results in profound increases in the magnitude of polyfunctional antigen-specifi c T cells after the MVA boost.
Studies of specifi c cellular responses and infection control in the vaccinated groups after SIV challenge
The robust immune responses stimulated by CpG DNA raised the question of whether there was an enhanced control of virus upon challenge with SIV. Although the present experiment was not designed as a challenge study (in terms of the limited numbers of animals per group and the unequal distribution of Mamu-A*01 ϩ animals), given the robust immune responses observed by adjuvanting with CpG DNA, we attempted to test the protective efficacy of the adjuvanted vaccine against a high dose mucosal challenge with SIV. The animals were thus challenged with a high dose (10 animal infectious doses per animal) of the highly pathogenic SIVmac 251 , delivered atraumatically via the rectal route, 19 wk after the fi nal MVA boost. Importantly, this protocol relied solely on protective responses directed to Gag and Pol antigens, because given the relative lack of cross-reactivity between SIV and the HIV Env or Nef used in the present vaccine ( 10 ) , no contribution from these antigens was expected. 2 wk after the challenge and coincident with the peak viremia, there was a signifi cant enhancement in the frequency of Gag-specifi c IFN-␥ ϩ CD8 ϩ T cells (mean of 7.8%, with two animals Ն 10%) in the group that received FL + TLR9-L relative to group 1 ( Fig. 3 A ) . In addition, there was a noticeable but statistically insignifi cant increase in such cells in the FL-alone group 2 or the FL ϩ TLR7/ 8-L group 4 ( Fig. 3 A ) . At week 10 or 24 after challenge, the magnitude of the Gag-specifi c IFN-␥ ϩ CD8 ϩ T cell response had reached a plateau at ‫ف‬ 1.7% for groups 2, 3, and 4 compared with a mean of 0.7% for group 1 ( Fig. 3 A ) . There was also a noticeable, although statistically insignificant, enhancement in the frequencies of Gag-specifi c CD4 ϩ T cells, particularly at week 24 ( Fig. 3 A ) . The responses after challenge at both early (week 2) and late (week 24) time points correlated well with the magnitude of the Gagspecifi c CD8 ϩ T cell responses noted after the second MVA boost ( Fig. 3 B , left and right, respectively). This suggested a direct link between the magnitudes of the vaccine-induced T cell response and expansion of antigen-specifi c T cells after viral challenge.
Furthermore, at weeks 2, 10, and 24 after challenge, there was an increase in the frequencies of polyfunctional, Gag-specifi c CD8 ϩ (not depicted) and CD4 ϩ T cells ( Fig.  3 C ) . The relative representation of polyfunctional cells within the Gag-specifi c CD8 ϩ T cell compartment was not altered by adjuvants (unpublished data). However, the relative representation of polyfunctional cells within the Gag-specifi c CD4 ϩ T cell compartment was enhanced at weeks 10 and 24 in groups 2, 3, and 4 relative to group 1 (Fig. S4 , available at http://www.jem.org/cgi/content/full/jem.20071211/DC1). Thus, administration of TLR9-L at the time of the primary DNA vaccination resulted in an enhanced magnitude of polyfunctional antigen-specifi c CD4 ϩ and CD8 ϩ T cells after challenge with SIV.
Although immune measurements often correlate with effi cacy, the ultimate test for any vaccine is the control of infection. Thus, we followed the viral titers in the SIVmac 251 -infected animals. Our vaccine contained only two antigens that were specifi c to SIV (Gag and Pol), and it is the CD8 ϩ T cells (and not antibody) stimulated by these antigens that are known to confer protection. The immunogen Env (the primary target for antibody-mediated neutralization) was encoded by an HIV env gene, and thus, neutralizing antibodies stimulated by HIV Env are not protective against SIV ( 43 ) . Thus, we were in eff ect evaluating the protective capacity of a CD8 ϩ T cell response that was specifi c to Gag and Pol.
One animal in group 1 and another in group 3 did not appear to have taken the challenge, as viral loads remained undetectable throughout the study and other parameters of immune activation (such as the frequency of CD4 ϩ T cells in the gut) remained normal. These two animals were excluded from the statistical analyses of viral loads. Challenge of unvaccinated animals with SIV resulted in a geometric mean peak viral load of 23 million copies per milliliter at week 2 ( Fig. 4,  A and B ) . Animals that received the DNA vaccine alone had a peak mean viral load of 7 million copies per milliliter. However, in the groups that received FL + TLR9-L or FL + TLR7/8-L, there was a 6.3 -8.5-fold reduction in the peak viral loads (3.6 million and 2.7 million copies per milliliter, respectively; Fig. 4, A and B ). Viral loads were followed for a longer term (up to 24 wk; Fig. 4 A ) . The unvaccinated animals reached a set-point load geometric mean of 2.5 million copies per milliliter by weeks 10 -24 ( Fig. 4 A ) . The animals in group 1 reached a geometric mean set-point value of ‫ف‬ 0.36 million copies per milliliter. In contrast, with the exception of one animal, there was a profound diminution of viral loads in the animals in group 3 ( Fig. 4 A ) . Three of the animals had a geometric mean of viral loads of 448 copies per milliliter, which was barely above the threshold of detection of 125 copies per milliliter ( Fig. 4 A ) . The animals that received FL or FL ϩ TLR7/8-L also had noticeably enhanced control of viral titers, although the eff ects were not as pronounced as in the FL ϩ TLR9-L group ( Fig. 4 A ) . In particular, there was a statistically signifi cant decrease in the cumulative viral loads, as measured by the area under the curve (AUC) for the entire 24-wk period after challenge, in the FL ϩ TLR9-L and FL ϩ TLR7/8-L groups relative to the unvaccinated group ( Fig. 4 C ) . There was a noticeable but statistically insignifi cant diff erence in the viremia reduction measured by the AUC between group 1 and groups 3 and 4.
from an independent study, in which eight monkeys (four Mamu-A*01 ϩ and four Mamu-A*01 Ϫ ) were vaccinated twice with a DNA vaccine encoding the SIV antigens gag, pol, env, nef, vpr, and vpu, followed by two boosts with MVA expressing the same antigens (unpublished data). The vaccination regimen was similar to the present study, but the critical diff erence was that all the antigens encoded by this vaccine were SIV specifi c. The viral loads were compared with viral loads in the unvaccinated group, which also consisted of eight animals (four Mamu-A*-01 ϩ and four Mamu-A*-01 Ϫ ).
Given the caveats noted, we addressed the potential effects of Mamu-A*01 by analyzing the viral loads within the Mamu-A*01 ϩ animals. As shown in Fig. 4 D , there was a signifi cant reduction in viral loads in groups 3 and 4 relative to group 5. Furthermore, there was a reduction in the loads in groups 3 and 4 relative to group 2, although this did not achieve statistical signifi cance. Furthermore, we analyzed whether the observed lack of viral control in response to vaccination without any adjuvants (group 1) was caused by the absence of Mamu-A*01 in group 1. We thus evaluated data similar for Mamu-A*-01 ϩ and Mamu-A*-01 Ϫ animals (unpublished data). In addition, recent work suggests that two other haplotypes, Mamu-B*08 and Mamu-B*17, also exert an infl uence on the immune control of SIV infection ( 44, 45 ).
There was no statistical diff erence in the viral loads between the Mamu-A*-01 ϩ versus Mamu-A*-01 Ϫ animals when analyzed for the viral loads at the peak (week 2) or set point (week 24) of viremia, and kinetics of viral load control were Plasma was collected at weeks 1, 2, 3, 7, 10, 18, and 24 after challenge and tested for SIV viral loads (SIV RNA copies/ml). Symbols represent the dynamics of viremia for each animal in the group. In groups 1 and 3, single animals remained uninfected over the entire challenge phase and were not included in the statistical analyses. (B) Viral titers at the peak of viremia at week 2 after SIV challenge. Each symbol represents an individual animal in the experimental group; bars represent the geometric mean frequencies Ϯ SEM. All vaccinated groups were compared by a nonparametric Mann-Whitney test. P Ͻ 0.05 was considered statistically signifi cant ( n ϭ 4 or 5). (C and D) AUC from weeks 1 through 24 was calculated for each animal in all experimental groups (C), or Mamu-A*01 -positive animals only in groups 2, 3, 4, and 5 (D). Log-transformed areas (AUC [log 10 ]) were used in the analysis. Error bars represent the median with range (C, n ϭ 5; D, n ϭ 2 or 3). Analysis of variance was used for the comparisons among the groups and adjusted for multiple comparisons with the Bonferroni method. P Ͻ 0.05 was considered signifi cant ( n ϭ 4 or 5). N.A., not available.
after challenge with SIV. Three critical issues deserve discussion: (a) the mechanism by which TLR9-L acts, (b) the correlates of protective immunity, and (c) the infl uence of Mamu-A*01 haplotypes on the observed results.
Mechanism of action of adjuvants
An important mechanistic question is whether the observed increases in immune responses were caused by enhanced DC numbers, activation of DCs, or both. Our data suggest that it is the TLR9-L, rather than FL, that mediated the enhanced immunogenicity, because animals that received FL alone showed no augmentation of immune responses. This is consistent with previous studies suggesting that, although FL alone is known to enhance immune responses to soluble antigens and DNA vaccines in mice ( 28, 29 ) , in humans it failed to enhance immune responses to protein antigens despite documented increases in DC numbers ( 33 ) . However, it is formally possible that TLR9-L and FL acted in a synergistic manner to enhance the immune response. FL is known to expand DCs in most tissues of the body, including dermal DCs in the dermal layer of the skin ( 49 ). Thus, it is possible that the increased numbers of dermal DCs at the local site of vaccination (i.d.) might have facilitated enhanced uptake of the DNA vaccine directly or by phagocytosis of apoptotic cells that had acquired the DNA vaccine in situ. In addition, increased DC numbers in the draining lymph nodes may have enhanced the likelihood of cross-presentation of antigens derived from apoptotic bodies of activated DCs migrating from the skin ( 50 ) . However, our data suggest that enhanced DC numbers alone do not lead to amplifi cation of cellular immune responses. It is thus likely that the major eff ect was mediated via TLR9-L stimulation.
Another mechanistic question is how the innate immune activation by TLR9-L versus TLR7/8-L translates into the observed eff ects on adaptive immune responses. Our data suggest that both TLR9-L and TLR7/8-L induce potent activation of myeloid DCs and monocytes in the blood. Such systemic eff ects on DCs were used as surrogate measures of innate immune activation caused by TLR-Ls in vivo. However, it must be stressed that such systemic eff ects are likely to have been secondary eff ects, mediated perhaps by the release of proinfl ammatory cytokines released systemically by the direct TLR-mediated activation of DCs and other cells at the site of vaccination ( 51 ) . In humans and macaques, TLR9 and TLR7 are preferentially expressed on pDCs, whereas TLR8 is expressed preferentially on myeloid DCs and monocytes ( 22, 32, 35 ) . Thus, TLR9-L and TLR7-L can directly activate only pDCs, whereas TLR7/8-L can directly activate both myeloid DCs and pDCs ( 22, 32, 35 ) . We observed a diminution in pDC numbers in the blood, which was likely caused by the rapid activation and translocation of such cells into the secondary lymphoid organs. In contrast, both TLR9-L and TLR7/8-L appear to potently activate myeloid DC and monocytes in vivo ( Fig. 1 ) . This is likely to have been caused indirectly, as a result of proinfl ammatory cytokines released by other cells, presumably pDCs ( 51 ) . In any case, it
We thus tested the animals for these haplotypes, and there were two Mamu-B*17 animals and one Mamu-B*08 animal within the entire cohort. One of the Mamu-B*17 animals was in group 1, and the other was in group 5. The Mamu-B*08 animal was in group 2. Thus, group 3 which displayed the best control did not contain any Mamu-B*08 or Mamu-B*17 animals. Collectively, these data suggest that the observed enhancement in immune responses and viral control in the FL + TLR9-L group are unlikely to be caused by Mamu-A*01 eff ects alone.
Correlates of protective immunity
We evaluated potential correlations between the immune responses and viral loads ( Fig. 5 ) . Importantly, there was a strong inverse correlation between the viral loads at the set point at week 24 and the magnitude of the Gag-specifi c IFN-␥ ϩ CD8 ϩ T cell response after a second MVA at primary phase at week 1 ( Fig. 5 A ) , memory phase at week 10 ( Fig. 5 B ) , or 2 wk after SIV challenge ( Fig. 5 C ) . Also, the frequencies of polyfunctional CD4 ϩ ( Fig. 5 D ) or CD8 ϩ ( Fig. 5 E ) T cells correlated with the control of viremia at week 24 after SIV challenge, suggesting the identifi cation of associates of protection after immunization. Additionally, we determined if preservation of central memory CD4 ϩ T cells correlated with the control of the viremia after the challenge, as previously reported ( 46, 47 ) ( Fig. 5 F ) . Percentages of CD95 ϩ CD28 ϩ CC chemokine receptor (CCR) 7 ϩ -expressing, central memory CD4 ϩ T cells measured in the blood 24 wk after challenge were well maintained in vaccinated monkeys and correlated inversely with viral loads at the viremia set point ( Fig. 5 F ) .
Finally, we evaluated the frequency of CD4 ϩ T cells in the gut, which have been shown to be destroyed rapidly during SIV infection. Vaccination has been shown to preserve these cells, especially the CD4 ϩ central memory T cells ( 48 ) . Our data suggest a strong correlation between vaccine-induced immunity and the frequency of CD4 ϩ T cells in the gut (Fig. S5 , available at http://www.jem.org/cgi/content/ full/jem.20071211/DC1). In particular, animals in groups 1 and 5 exhibited a rapid diminution in the frequency of intestinal CD4 ϩ T cells (Fig. S5 A) . In contrast, in animals vaccinated with FL or FL + TLR9-L or FL + TLR7/8-L, there was a pronounced reconstitution of the CD4 ϩ T cells at week 18 after challenge (Fig. S5, A and B) . Furthermore, there was a striking inverse correlation between the frequency of CD4 ϩ T cells in the gut and the viral loads in plasma ( Fig. 5 G ) , signifying an association of viral control and loss of intestinal CD4 ϩ T cells, as well as a direct correlation between the magnitude of the Gag-specifi c CD8 ϩ T cell response at 2 wk after SIV challenge ( Fig. 5 H ) .
DISCUSSION
The results presented in this paper suggest that activating DCs with TLR9-L at the time of the initial immunization with a DNA vaccine results in an enhanced antigen-specifi c CD8 ϩ T cell response and improved control of viral loads TLR9-L versus TLR7/8-L ( Fig. 1 ) . Whether this infl uenced the diff erences in the magnitude of the adaptive immune responses induced by TLR9-L versus TLR7/8-L remains to be determined.
Correlates of protective immunity
The magnitude of the antigen-specifi c IFN-␥ ϩ CD8 ϩ T cell response after MVA challenge and after SIV-infection was inversely correlated with the viral loads ( Fig. 4, D -F ) and is striking that the TLR7/8-L failed to enhance the magnitude of T cell response despite potent innate immune stimulation, as judged by DC activation in the blood. One possibility is that the TLR7/8-L, which is a small molecule, administered in a soluble form rapidly diff uses from the site of vaccination. In fact, recent experiments show that direct conjugation of TLR7/8-L to a protein antigen results in an enhanced immune response ( 22 ) . In addition, we observed diff erences in the expression patterns of CD86 and CD80 in response to magnitude and quality of immune responses induced by DNA vaccines. This may provide a solution to the problems associated with the suboptimal immunogenicity of DNA vaccines in humans. In particular, our data suggest that TLR9-L may serve as a useful adjuvant in enhancing specifi c immunity in an HIV infection model. It is important to stress that in the vaccine used in the present study, only G ag and P ol were SIV specifi c, whereas the other antigens, including Env, were HIV specifi c. Therefore, the elicitation of robust, high quality CD8 ϩ T cell responses alone, in the absence of a neutralizing antibody response, can exert a major eff ect on viral control. The additional benefi ts in protection that are likely to accrue from using a vaccine encoding all antigens that are SIV specifi c remain to be determined. Finally, the potential clinical utility of such a study is critically dependent on strategies that circumvent the onerous FL administration schedule. One such strategy might involve formulating FL into nanoparticles that slowly release the cytokine over the course of a few days.
MATERIALS AND METHODS

Animals.
A cohort of 25 adult Indian rhesus macaques ( Macaca mulatta ) was maintained in the Yerkes National Primate Research Center and Field Station facility. Animals were cared for under guidelines established by the Animal Welfare Act and the NIH " Guide for the Care and Use of Laboratory Animals, " with protocols approved by the Emory University Institutional Animal Care and Use Committee. NHPs were sex and weight matched and divided into fi ve groups of fi ve animals each ( Table I ) Injections and reagents. Animals were injected subcutaneously for 14 consecutive days (day 1 -14) with 100 g/kg/d of human FL protein (PBS diluted) provided by Amgen. Cloning of pGA1-SHIV 89.6 VLP pDNA has been previously described ( 10 ) . pDNA was purifi ed by QIAGEN and injected i.d. at 2 mg per animal in PBS at weeks 2 (day 15) and 11 of the study. In group 3, pDNA was mixed and co-injected i. Challenge and viral loads. All monkeys were challenged by a rectal inoculation of 10 animal infectious doses per animal of SIVmac 251 (provided by N. Miller, National Institute of Allergy and Infectious Diseases, Bethesda, MD) at week 77 of the trial. Plasma samples were collected at the time points indicated in the fi gures (weeks 1, 2, 3, 7, 10, 18, and 24 after challenge) and tested for viral RNA using the SIVmac RNA bDNA assay (Bayer Diagnostics). The detection threshold of the bDNA assay was 125 copies per milliliter.
Cell isolation and staining. PBMCs were isolated with a standard method from heparinized or citrated blood samples. Intestinal mucosal cells were isolated from rectal biopsy samples. Rectal biopsy pellets were washed with HBSS medium twice and resuspended in RPMI 1640 containing antibiotics. Tissues were digested for 1.5 h in the presence of collagenase (type 4; Worthington) and DNase (type 1; Roche). Digested pellets were disrupted by pippetting and were fi ltered twice through a cell strainer. Both PBMCs and mucosal cells were resuspended in PBS containing 10% FBS and were with CD4 ϩ T cells levels in gut tissue ( Fig. 5 D ) , which was consistent with numerous previous studies ( 52 -54 ) . However, the frequency of IFN-␥ ϩ IL-2 ϩ TNF-␣ + polyfunctional CD8 ϩ and CD4 ϩ T cells after challenge showed an even stronger inverse correlation with the viral loads ( Fig. 5, D and E ) , suggesting that not only the magnitude but also the quality of the T cell response were critical correlates of protection ( 36, 38, 39 ) . In the case of TLR7/8-L, there was a statistically signifi cant lowering of viral loads despite no increase in the frequency of antigen-specifi c CD8 ϩ T cells ( Fig. 4, B and C ) . This implies that TLR7/8-L might be inducing a diff erent quality of T cells, not measured in this study, that results in enhanced control of infection.
Infl uence of Mamu-A*01 and other haplotypes
Previous studies have suggested that animals expressing the MHC class I allele Mamu-A*01 are particularly effi cient at controlling SIV replication ( 40, 41 ) , whereas recent experiments suggest that this may not be so ( 42 ) . Our analysis of the magnitude of the Gag-specifi c IFN-␥ ϩ CD8 ϩ T cell response only in Mamu-A*01 ϩ animals indicated ( Fig. 2 E ) that the Gag-specifi c IFN-␥ ϩ CD8 ϩ T cell responses were enhanced signifi cantly in group 3 relative to group 2 or 4, suggesting that the adjuvant eff ects of TLR9-L were not simply caused by the unequal distribution of Mamu-A*01 animals. Furthermore, the CD8 ϩ T cell responses against HIV Env protein, which does not demonstrate Mamu-A*01 -specifi c epitope dependence, were enhanced only in group 3, which was treated with FL and TLR9-L ( Fig. 2 C ) . Furthermore, our analysis of the viral loads within the Mamu-A*01 ϩ animals ( Fig. 4 D ) showed a signifi cant reduction in viral loads in groups 3 and 4 relative to group 5. There was also a reduction in the loads in groups 3 and 4 relative to group 2, although this did not achieve statistical signifi cance. Finally, our analysis of data from an independent study, in which eight monkeys (four Mamu-A*01 ϩ and four Mamu-A*01 Ϫ ) were vaccinated twice with a DNA vaccine encoding the SIV antigens gag, pol, env, nef, vpr, and vpu, followed by two boosts with MVA expressing the same antigens, failed to reveal an eff ect for the Mamu-A*01 haplotype on viral loads (unpublished data). There was no statistical diff erence in the viral loads between the Mamu-A*-01 ϩ versus Mamu-A*-01 Ϫ animals when analyzed for the viral loads at the peak (week 2) or set point (week 24) of viremia, and kinetics of viral load control were also similar for Mamu-A*-01 ϩ and Mamu-A*-01 Ϫ animals (unpublished data). As discussed, neither group 3 nor group 4 contained any Mamu-B*08 or Mamu-B*17 animals, and, thus, these haplotypes cannot have contributed to the observed enhancements in viral controls. Collectively, these data suggest that the observed enhancements in immune responses and viral control in the FL + TLR9-L group are unlikely to be caused by Mamu-A*01 eff ects alone.
Perspectives
In summary, these data indicate that strategies that enhance the activation of DCs may be benefi cial in enhancing the IFN-␥ -and/or TNF-␣ -and/or IL-2 -producing T cells after the last MVA boost. Fig. S4 demonstrates the quality of Gag-specifi c, IFN-␥ -and/or TNF-␣ -and/or IL-2 -producing CD4 ϩ T cells after SIV challenge. Fig. S5 shows the frequency of CD4 ϩ T cells in the intestine after SIV challenge. Online supplemental material is available at http://www.jem.org/cgi/ content/full/jem.20071211/DC1. ICC staining. Approximately 2 ϫ 10 6 PBMCs were stimulated with total pools of SIV-Gag or HIV-Env proteins at the fi nal concentration of 2 g/ml (15-mers overlapping by 11; courtesy of the NIH AIDS Reagent Program) in 5-ml polypropylene tubes in RPMI 1640 medium containing 10% FBS, and anti -human CD28 and anti -human CD49d (1 g/ml each; BD Biosciences) in a fi nal volume of 500 l. Ovalbumin peptide (SIINFEKL) -stimulated PBMCs were used as negative controls. After 2 h of incubation at 37 ° C, 20 l of medium containing 10 g/ml Brefeldin A was added, and cells were cultured for an additional 4 h at 37 ° C at an angle of 5 degrees. Cells were surface stained with fl uorochrome-conjugated antibodies to CD8 and CD4. Cells were incubated with fl uorochrome-conjugated antibodies to CD3, IFN-␥ , IL-2, and TNF-␣ in perm/wash solution (BD Biosciences) for 20 min at 4 ° C. Cells were washed twice with Perm/wash, washed once with PBS/10% FBS, and resuspended in 2% PFA in PBS. Approximately 500,000 lymphocytes were acquired for analysis.
ELISPOT. MULTISCREEN 96-well fi ltration plates (Millipore) were coated with the anti -IFN-␥ capture antibody at a concentration of 5 g/ml in PBS and refrigerated overnight. Plates were washed two times with RPMI 1640 medium and blocked with RPMI 1640 containing 10% FBS for 1 h at 37 ° C. Plates were washed fi ve more times with RPMI 1640/10% FBS medium, and cells were seeded in duplicates in 100 l of complete medium at concentrations of 2 ϫ 10 5 cells per well. SIV-Gag or HIV-Env total peptide pools were added in a volume of 100 l in RPMI 1640/10% FBS medium resulting at the end concentration of 1 g/ml of each peptide in reaction. Cells were cultured at 37 ° C for ‫ف‬ 20 -36 h under a 5% CO 2 atmosphere. Plates were washed six times with wash buff er (PBS with 0.05% Tween 20) and incubated with 1 -2 g of respective biotinylated anticytokine antibody diluted in wash buff er containing 2% FBS. Plates were incubated for 2 h at 37 ° C and washed six times with wash buff er. Avidin -horseradish peroxidase (Vector Laboratories) was added to each well and incubated for 60 min at 37 ° C. Plates were washed fi ve times with wash buff er, and spots were developed with stable DAB used as substrate (Research Genetics). Spots were counted by using an automated ELISPOT reader (CTL). Data were normalized for the background by control samples stimulated with an ovalbumin peptide (SIINFEKL) and are represented as several spot-forming cells per 10 6 PBMCs. The following capture and detection antibody pairs were used: anti -human IFN-␥ capture antibody (clone B27; BD Biosciences) and antihuman IFN-␥ detection antibody (clone 7-B6-1; Diapharma Group, Inc.).
Statistical analysis. All data were analyzed using Prism software (GraphPad Software, Inc.). Cellular responses, mucosal CD4 ϩ T cell numbers, and viral loads data were compared using the nonparametric Mann-Whitney test. P Ͻ 0.05 was considered statistically signifi cant. For viremia control, AUC from weeks 1 to 24 was calculated for each infected animal. Log-transformed areas (AUC [log 10 ]) were used in the analysis. Analysis of variance was used for the comparisons among the groups and adjusted for multiple comparisons with the Bonferroni method; P Ͻ 0.05 was considered signifi cant. For correlation analysis, all datasets were calculated for correlation effi ciency and were considered signifi cant at P Ͻ 0.05. Spearman ' s rank correlation coeffi cient values were evaluated and represented (r).
Online supplemental material. Fig. S1 represents the experimental design of the trial. Fig. S2 shows the gating strategy for specifi c, cytokineproducing CD4 ϩ and CD8 ϩ T cells. Fig. S3 shows the quality of Gag-specifi c
